Opioid Receptor Modulation of Hedonic Taste Preference and Food Intake: A Single‐Dose Safety, Pharmacokinetic, and Pharmacodynamic Investigation With GSK1521498, a Novel μ‐Opioid Receptor Inverse Agonist
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Endogenous opioids and μ‐opioid receptors have been linked to hedonic and rewarding aspects of palatable food intake. The authors examined the safety, pharmacokinetic, and pharmacodynamic profile of GSK1521498, a μ‐opioid receptor inverse agonist that is being investigated primarily for the treatment of overeating behavior in obesity. In healthy participants, GSK1521498 oral solution and capsule formulations were well tolerated up to a dose of 100 mg. After single doses (10–150 mg), the maximum concentration (C max) and area under the curve (AUC) in plasma increased in a dose‐proportional manner. GSK1521498 selectively reduced sensory hedonic ratings of high‐sugar and high‐fat dairy products and caloric intake of high‐fat/high‐sucrose snack foods. These findings provide encouraging data in support of the development of GSK1521498 for the treatment of disorders of maladaptive ingestive behavior or compulsive consumption.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The use of analogue scales in rating subjective feelings
BOND, A., & LADER, M. (1974) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1974.tb02285.x · Cited by 1,972
Food reward: brain substrates of wanting and liking
Berridge, K. C. (1996) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(95)00033-b · Cited by 1,901
Peciña, S., & Berridge, K. C. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02102-8 · Cited by 405 · cited 1×
“In contrast, μ-opioid receptor antagonists, such as naloxone and naltrexone, reduce food intake of palatable or high-caloric food and drinks.(16-33) In humans, the μ-opioid receptor antagonists, including naloxone, naltrexone, and nalmefene, have been shown to decrease short-term food intake (decreases between 11% and…”
BackgroundDrewnowski, A., Krahn, D., Demitrack, M., Nairn, K., & Gosnell, B. (1995) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/61.6.1206 · Cited by 197 · cited 3×
“Participants evaluated 20 samples of sweetened commercial dairy products, with varying sucrose and fat content, for taste and hedonic preference as previously described and validated for naloxone by Drewnowski and colleagues.(41) The sucrose/fat ratios of the dairy products were identical to those previously reported.”
BackgroundMethodResultWeerts, E. M., Kim, Y. K., Wand, G. S., Dannals, R. F., Lee, J. S., Frost, J. J., & McCaul, M. E. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301440 · Cited by 147
Cited by
The contribution of brain reward circuits to the obesity epidemic
Stice, E., Figlewicz, D. P., Gosnell, B. A., Levine, A. S., & Pratt, W. E. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.001 · Cited by 274
“…have a favorable safety and tolerability profile, has been shown to reduce hedonic ratings of high-sugar and high-fat dairy products, to reduce caloric intake of snack foods, an to reduce fMRI-assessed activation of the amygdala induced by palatable food (Nathan et al., 2012; Rabiner et al., 2011).”
BackgroundPsychopharmacological advances in eating disorders
Himmerich, H., & Treasure, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1383895 · Cited by 119
Heal, D. J., Hallam, M., Prow, M., Gosden, J., Cheetham, S., Choi, Y. K., Tarazi, F., & Hutson, P. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699607 · Cited by 28
Metadata
- Authors
- Nathan, P. J., O'Neill, B. V., Bush, M. A., Koch, A., Tao, W. X., Maltby, K., Napolitano, A., Brooke, A. C., Skeggs, A. L., Herman, C. S., Larkin, A. L., Ignar, D. M., Richards, D. B., Williams, P. M., & Bullmore, E. T.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2012-04
- Volume
- 52
- Issue
- 4
- Pages
- 464-474
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W1978188503
- Cited by
- 47
- References
- 5
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.